Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling

•Liquid biopsy and comprehensive genomic profiling (CGP) of ctDNA is increasingly used in NSCLC•Clinical outcomes were evaluated using real-world data•Real-world response to targeted therapy was similar for liquid and tissue biopsy•Routine clinical use of liquid biopsy CGP can reliably guide therapy selection